Immunic secures $400m fund to support commercial-stage development

Immunic has announced an oversubscribed backstage placement of up to $400m, strengthening its determination from an R&D-focused organisation into a commercial-stage entity.

The placement was led by existing capitalist BVF Partners and joined by entities specified arsenic Avidity Partners, OrbiMed, Trails Edge Capital Partners, TCGX, Vivo Capital and different organization investors.

The institution volition besides usage the proceeds for completing its ongoing Phase III ENSURE studies of vidofludimus calcium successful relapsing aggregate sclerosis (MS), with top-line results anticipated by the extremity of this year.

Immunic aims to taxable a caller cause exertion (NDA) successful the US by mid-2027 and targets regulatory support successful 2028. Parallel efforts are focused connected preparing for vidofludimus calcium’s imaginable commercialisation, including expanding aesculapian and commercialized teams.

Plans besides see launching a Phase III objective programme successful superior progressive aggregate sclerosis (PPMS) aboriginal this year. The institution estimates this proceedings volition necessitate astir three-and-a-half to 4 years to complete.

Vidofludimus calcium is designed arsenic a first-in-class therapy that targets some neuroprotection via Nurr1 activation and inflammation simplification done selective dihydroorotate dehydrogenase (DHODH) inhibition.

Under the backstage placement terms, Immunic has agreed with prime accredited investors to contented 229.1 cardinal pre-funded warrants astatine $0.873 per warrant, yielding upfront proceeds of $200m.

Investors volition besides person warrants for up to an further 229.1 cardinal shares (or pre-funded warrants) astatine the aforesaid terms for the remaining $200m. These warrants are acceptable to expire connected the earlier of 30 days pursuing nationalist merchandise of Phase III ENSURE information oregon connected 17 February 2031.

Leerink Partners served arsenic pb placement cause alongside B Riley Securities, Brookline Capital Markets, Guggenheim Securities, LifeSci Capital, Stifel and William Blair.

Immunic intends to usage the nett proceeds for operations and wide purposes, backing activities into precocious 2027.

Immunic co-founder and CEO Dr Daniel Vitt said: “I would similar to convey BVF and the different investors successful the consortium for joining our travel towards imaginable regulatory support of vidofludimus calcium.”

The committee volition statesman searching for a caller CEO with MS commercialized expertise arsenic Dr Vitt transitions to a caller enforcement relation focused connected technological strategy and portfolio advancement.

"Immunic secures $400m money to enactment commercial-stage development" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.